Words matter. These are the best Vivek Ramaswamy Quotes, and they’re great for sharing with your friends.
I’ve said all along that we’re building Axovant as a lasting company for the long run, not to hand over that upside to a pharma company in the future.
I would not have had the same personal commitment to Alzheimer’s disease if it had not been for my mother and my upbringing.
The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit.
I believe the pharma company of the future isn’t going to be old-school.
I think dementia is the major healthcare threat to our economy and our security. It’s a ticking time bomb – we have a whole generation of baby boomers that are going to age, many progressing to get Alzheimer’s – which disproportionately affects women and minorities.
In contrast to how tech firms want to disrupt and break things – developing drugs must be incremental and step-by-step. This is the kind of work that involves people putting their lives on the line every day with clinical trials.
The thing in Alzheimer’s disease to remember, and we remember this all the time at Axovant, is we don’t fully understand the way the actual underlying disease works.
I take a lot of personal pride and motivation to be able to make a difference in areas that may fall through the cracks in R&D across the industry.
The more general skepticism about another millennial that likes to claim they’re disrupting another industry – that doesn’t serve me well.
From a personal standpoint, I consider myself much more of an accidental entrepreneur. I was involved in the entrepreneurship club at Harvard, but I heard of it only because it was new on campus.
It’s a great disappointment as a leader in the biotech industry that with all the amazing things the drug industry has done in the last couple of decades, we have not made a single major advance, have not not developed a single new chemical entity approved for the treatment for Alzheimer’s disease.
Roivant does not view – and has never viewed – Axovant as simply a ‘vehicle’ for developing intepirdine, but instead as a platform for the development of high-impact drugs in dementia and the neuroscience field more generally.
If we can validate our scientific bets in the clinic, if we can bring valuable new treatments to patients that need them, that will be our ultimate measure of success.
I’d encourage more young people to apply their talents beyond finance and consulting and to think about reshaping how medicines are brought to market and how the business is run.
